Solianis Holding AG is a Swiss Medical device company developing a non-invasive, continuous glucose monitoring device for diabetic patients. This prototype was inspired by the realization that diabetics need a way to more effectively manage their blood glucose throughout the day, without the bloodshed. Mario Stark is revitalizing a concept in diabetes control that many have tried and few have succeeded.

The design of Solianis' non-invasive device includes monitoring as often as once a minute. Although there have been previous generations of non-invasive continuous glucose monitoring devices, they have been more adequately deemed minimally invasive. Even the Glucowatch extracted fluid from the skin, which constitutes it being minimally invasive. Perhaps the failure of true success has been due to the technology chosen not being adequate to measure glucose throughout the day in a variety of circumstances. The Solianis device is truly non-invasive. Solianis realizes the real issue is to develop a non-invasive glucose monitor that works under daily life conditions, uninterrupted. Under these conditions a lot of things happen. Factors that can affect the glucose measure include: changes in blood flow, micro-vascular circulation, sweat, the humidity and temperature fluctuations, and the thickness of the skin. All these physiological changes induce changes in the sensor that may affect the measurement of glucose. Solianis has developed a multi-sensor approach that will measure these perturbing factors and include them into the calculation of glucose for more accuracy than previous non-invasive glucose monitoring sensors.

If somebody could please bring a device like this to fruition that will accurately, continuously and conveniently measure the fluctuations in blood sugar without drawing blood - that somebody will mitigate the frustration of millions of diabetics. If that somebody happens to enjoy investing - I'd venture to say this is a potential ten bagger. A biomedical position like this in your portfolio is worth its weight in the convenience it will give diabetics. Now I'm going to sound like Jim Cramer -- I don't own the stock, but I will own the device for my charitable trust: ME!